The notion of a digital dollar for the United States has been increasingly in the news over the last month. Research into a potential Central Bank Digital Currency (CBDC) was called for by an executive order from President Biden in March, and it’s easy to see why: between efforts abroad from China to make moves in the space, to the increasing adoption rate of cryptocurrencies and other faster payments technologies, it’s clear to see that the technology has caught up to the vision, and implementation could offer significant advantages. However, not everyone thinks that a Federal Reserve-backed digital currency is
Everyone wants their weed these days, with all different ways to consume the plant. Some want to smoke it, some want to eat it in edibles, some only want to vape it, some take their bong hits, some rub it on their skin, some put oil under their tongue, and some swallow down tinctures or […]
HONG KONG, Mar 25, 2022 - (ACN Newswire) - Kindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Company", together with its subsidiaries, collectively the "Group"; stock code: 9960.HK), a leading independent esoteric clinical testing service provider in China, today announced its audited annual results for the year ended 31 December 2021 ("2021" or the "Year").
During the period under review, the Group recorded total revenue of RMB930.67 million, representing a year-on-year increase of 4.4%. Revenue from non-COVID-19-related testing services was RMB868.57 million, an increase of 12.3%. The Group's consolidated gross profit was up by 5.4% year-on-year to RMB485.77 million, while the consolidated gross profit margin rose by 0.5% year-on-year to 52.2%. Cash and cash equivalents amounted to RMB1,796.7 million, a growth of 113.6% year-on-year. The non-COVID-19-related testing services segment recorded results of RMB197.18 million, an increase of 17.5% year-on-year. The Board has resolved not to distribute a dividend for FY2021.
Focused on specialty esoteric testing services and vigorously developed related services in six major specialty areas
Since its inception in 2003, the Group has been focusing on esoteric clinical testing services and is one of the first companies in China entering the esoteric testing service industry. During the period under review, the Group covered more than 3000 hospitals, in which over 60% are Class III hospitals, added three new laboratories and its esoteric testing volume exceeded 1.68 million, with positive growth in all six major esoteric testing specialty areas.
-- Hematology testing: The Group introduced 50 new testing items and added the Shanghai Xinnuo Baishi Medical Laboratory. During the period, the Group achieved revenue of RMB535.27 million and segment results of RMB152.57 million, representing a year-on-year increase of 14% and 15.7%, respectively. -- Neurology testing: The Group launched six new projects covering diseases such as Alzheimer's disease and myasthenia [gravis] and also added 143 partnering Class III hospitals. The Group recorded revenue of RMB89.85 million and segment results of RMB14.06 million during the period, a year-on-year increase of 18.2 and 11.6%, respectively. -- Maternity-related testing: The Group added the diagnosis of gestational syndromes during the period, and recorded revenue of RMB52.25 million and segment results of RMB3.55 million, representing a year-on-year increase of 0.2% and 0.5%, respectively. -- Genetic disease and rare disease testing: During the period, the Group realized revenue of RMB43.50 million and segment results of RMB5.43 million, representing a year-on-year increase of 20.2% and 126.4%, respectively. Sales of multiple steroid hormone tests doubled year-on-year. -- Infectious disease testing: The Group introduced 28 new testing items and added the Wuhan Kindstar Zhenyuan Medical Laboratory, achieving revenue of RMB51.97 million and segment results of [RMB]9.78 million during the period, representing a year-on-year increase of 3% and 33.2%, respectively. -- Oncology testing: The Group launched new testing service items for various types of cancer, including intestinal cancer, cervical cancer, bladder cancer and liver cancer, achieving revenue of RMB8.62 million and segment results of RMB0.83 million during the period, 13.4% and 82.5% higher than the same period last year. -- Others: The Group added more than 20 scientific research service projects in the areas of research services, CRO and new testing services, achieving revenue of RMB19.46 million and segment results of RMB5.99 million during the period, representing a year-on-year growth of 36.1% and 35.1%, respectively.
Persistent R&D investment to develop and expand new specialty esoteric testing business lines
As at 31 December 2021, the Group's R&D expenses amounted to RMB90.33 million, a year-on-year increase of 20.0%.The Group had 112 new R&D projects, 17 patents were pending or granted and 23 scientific research articles were published throughout the year. During the period under review, the Group stepped up its efforts in promoting the development of specialty esoteric testing services in China and expanding the scope of such services to cover cardiovascular diseases, ophthalmology, rheumatology and immunology.
-- Cardiovascular diseases: The Group focused on the R&D of biomarkers for cardiovascular diseases such as coronary heart disease, acute myocarditis and acute myocardial infarction. It also conducted verification studies on the clinical value of biomarkers. -- Ophthalmology: The Group actively explored opportunities in ophthalmic structured esoteric testing services and its R&D covered testing solutions for hereditary oculopathy, infectious oculopathy and autoimmune oculopathy. -- Rheumatology and immunology: The Group began the initial development of six types of disease and drug detection projects, covering sicca syndrome, rheumatoid arthritis, ankylosing spondylitis, gout, antiphospholipid syndrome and allopurinol detection.
Entered the IVD reagents field and optimized immune repertoire deployment
Wuhan Haixi Life Science Technology Co., Ltd., which the group owns a controlling stake, is a high-tech enterprise based on the R&D, manufacturing and sales of esoteric testing reagents providing systematic, comprehensive "high-precision and cutting edge" testing reagent products. The Group's main products, namely reagent kits for JAK2 genes and V617F mutations (PCR-fluorescent probe method) and reagent kits for leukemia fusion genes qualitative testing (PCR-fluorescent probe method) will enter the clinical trial stage of NMPA registration. During the period under review, the Group established its business presence in the field of IVD reagent kits in the upstream industry chain by holding shares in Wuhan Haixi Life Science Technology Co., Ltd.
As an important next-generation sequencing technology, the immune repertoire sequencing technology may bring disruptive changes to the industry in the future. During the period under review, the Group established Wuhan Kindstar Biotechnology Co., Ltd., which will focus on the application and development of the immune repertoire technology in multiple disciplines and explore the biopharmaceutical and immunotherapy pathways. In addition, to further improve its immune repertoire layout, the Group invested in Shenzhen Neoimmune Co., Ltd., a leading immune repertoire enterprise in China. Looking ahead, the two parties will commence strategic cooperation in the immune repertoire segment.
Strategy and Prospects
The Group will continue to consolidate its leading position in esoteric hematology testing in China and replicate its successful experience in hematology to expedite the growth of its specialty esoteric testing business in areas such as genetic diseases, rare diseases, infectious diseases, oncology and neurology. In the next three to five years, the Group will enter several new areas of specialty esoteric testing. At the same time, the Group is also committed to building strong relationships with a wide range of participants in the clinical esoteric testing industry (including doctors, hospitals, pharmaceutical companies, contract research institutions, academic institutions and regulatory agencies), deepening existing strategic partnerships, and expanding the existing cooperation network. Since its listing, the Group has attached great importance to opportunities for horizontal and vertical integration in the industrial chain. In the future, the Group will steadily achieve a strategic and forward-looking layout through investment, integration and empowerment, in order to boost its growth.
Huang Shiang, Chairman and Chief Executive Officer of Kindstar Globalgene, expressed full confidence in the future of China's esoteric clinical testing industry. He said, "Due to increasing public health awareness and an aging population in China, the demand for clinical tests has continued to increase. In recent years, China's esoteric clinical testing market has been growing faster than its routine testing market, and the Company has strived to develop and introduce advanced technologies to meet the enormous unmet medical demand in the country. Looking ahead, we will actively overcome the various uncertainties caused by the COVID-19 pandemic, while continuing to work hard to maintain the steady growth of our existing esoteric clinical tests, and develop and launch new services in specialty areas, thereby contributing to the precise diagnosis and advancement of treatments in specialty areas in China."
About Kindstar Globalgene Technology, Inc. Kindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Group"; stock code: 9960.HK) is a leading independent esoteric clinical testing service provider and a major provider of hematology esoteric testing services in China. It has built a comprehensive testing portfolio, a broad hospital network and advanced technology platforms and also boasts the largest esoteric testing portfolio among all independent esoteric testing providers in China, with more than 3,500 tests on its service menu and offering one of the most extensive hematology testing portfolios worldwide, including over 2,300 testing items in the field. The Group primarily targets specialty areas with substantial growth potential or that can create significant synergies with its esoteric hematology testing services, including genetic diseases and rare diseases, infectious diseases, oncology and neurology. The Group was listed on the Main Board of the Hong Kong Stock Exchange on 16 July 2021. Over the past 18 years, the Company has developed more than 1,100 testing items entirely in-house, and introduced approximately 2,400 testing items developed by or under license from third parties. The Group serves more than 3,000 hospitals in China, of which more than 1,500 are Class III hospitals, including all of the top 20 hospitals in the nation. The Group's mission is to offer a broad range of high-quality specialty testing services to patients and physicians worldwide, and to promote the application of precision diagnostics and medicine.
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comKindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Company", together with its subsidiaries, collectively the "Group"; stock code: 9960.HK), a leading independent esoteric clinical testing service provider in China, today announced its audited annual results for the year ended 31 December 2021 ("2021" or the "Year").
HONG KONG, Mar 25, 2022 - (ACN Newswire) - Analogue Holdings Limited ("Analogue" or the "Company", together with its subsidiaries, collectively the "Group") (stock code: 1977), a leading electrical and mechanical ("E&M") engineering service provider in Hong Kong, today announced its annual results for the year ended 31 December 2021 ("the Year" or "FY2021") with revenue and net profit growth, posting a solid performance amid the pandemic and global uncertainty.
Highlights -- Total revenue reached HK$5,350.7 million, an increase of 10.8% compared with adjusted revenue in FY2020 -- Profit attributable to owners of the Company grew 4.3% year-on-year to HK$314.3 million -- Revenue from maintenance services increased 7.2% to HK$945 million -- High dividend payout ratio maintained at 50.2%
During the Year, the Group's total revenue increased by 4.4% year-on-year to HK$5,350.7 million, mainly driven by both Building Services and Environmental Engineering segments. After adjusting the revenue for FY2020 from Transel Elevator & Electric Inc. ("TEI"), which has been reported as an associate of the Group since August 2020, the Group's total revenue would have increased by 10.8% year-on-year. In particular, revenue from maintenance services, a source of recurring income, increased by 7.2% year-on-year to HK$945 million, accounting for an increased proportion to 17.7% of the total revenue. Gross profit amounted to HK$878.4 million, with gross profit margin at 16.4%. Profit attributable to owners of the Company grew by 4.3% year-on-year to HK$314.3 million, even in the absence of such wage subsidies as the Government's "Employment Support Scheme" in 2020, which is evidence that the Year is most encouraging.
The Board has proposed a second interim dividend of HK7.25 cents per share. Together with the first interim dividend of HK4.02 cents per share, the total dividend for the Year amounted to HK11.27 cents per share, representing a high dividend payout ratio of 50.2%.
The Group has drawn on its exceptional project execution capability to deliver on the order book throughout 2021. Contracts-in-hand reached approximately HK$11,309 million as at 31 December 2021. Tendering activities remained active during the reporting period, with a total of 1,676 tenders valued at over HK$1 million each.
Dr. Otto Poon Lok-to, Chairman of Analogue Holdings Limited, said, "In 2021, although the E&M engineering sector was less affected by COVID-19 when compared with other industries, we still faced various challenges, such as interruptions in tendering for public works projects, high material and labour costs, etc. At Analogue, we upheld our motto 'We commit, We perform, We deliver' while doubling efforts to overcome challenges, which included optimising all facets of operation. In terms of business mix, we intentionally increased the proportion of contributions from maintenance services to ensure a stable source of income. Regarding geographical expansion, we leveraged our successful track record in Hong Kong, Macau and Mainland China to establish footholds overseas. As an advocate of innovation, we continued to direct our efforts towards enriching business operations through applications of new technologies. Our strategies have resulted in increased revenue and profitability in FY2021 despite the testing environment."
With active project delivery throughout the Year, Building Services segment's contracts-in-hand reached HK$4,892 million as of 31 December 2021. As an early adopter of cutting-edge building technologies, the Group pioneered the first high-rise building in Hong Kong using the advanced Modular Integrated Construction ("MiC") method. This track record won it HK$150 million worth of MiC contracts in FY2021. In light of the surging demand for MiC, the Group has been expanding its Multi-trade Integrated Mechanical, Electrical and Plumbing ("MiMEP") facilities and developing its proprietary ATAL Building Services Prefabrication and Modularisation Construction Technology ("ABSPM") to further improve the speed, cost, safety, and quality of construction work. During the Year, the Group participated in the building services work for one of the biggest data centres and secured additional installations and maintenance projects from major data centre operators in Hong Kong. Other key projects secured include a major hospital term contract and seven residential projects worth approximately HK$800 million, as well as a major contract for a Hong Kong racehorse training facility located in Guangzhou.
Environmental Engineering segment's contracts-in-hand amounted to HK$4,977 million. During the Year, the Group won four term contracts for the Hong Kong Government's Water Supplies Department that brings citywide benefits, covering all waterwork installations throughout the territory, such as the maintenance of mechanical and electrical equipment, instrumentation equipment, water quality monitoring equipment and plants. In addition, the Group took part in the iconic project of the Hong Kong Government Drainage Services department to upgrade the existing sewage treatment works to become the effluent polishing plant in Yuen Long which has been upgraded to meet future development needs, including expanding the treatment capacity from 70,000m3/day to 150,000m3/day. The deployment of the most advanced sewage treatment technologies featuring green design and community provisions will create an exemplary community asset and a more sustainable Hong Kong. The Group also commenced the operation and maintenance works for the sewage treatment plants in San Wai and power stations in Castle Peak and Black Point during the Year.
Information, Communications and Building Technologies ("ICBT") segment's contracts-in-hand increased by 2.7% to HK$877 million during the Year. To contribute to the development of Hong Kong's "Smart City" and "Smart Economy" initiatives, the Group rolled out a number of ICBT projects, including its proprietary Internet of Things ("IoT") applications for Smart Washrooms, Retro-commissioning (RCx) of electrical and mechanical systems, Indoor Environmental Quality (IEQ) Monitoring, Indoor Positioning and Video Analytics, as well as its in-house developed Cloud-based AI Energy Management Platform during the Year. In particular, the AI Energy Management Platform, IoT applications and Video Analytics technology have been chosen by more than 20 shopping malls, while its Photovoltaic ("PV") systems will be installed in more than 100 schools and NGOs. Such continuous contributions to streamlining digital processes and applying them will ultimately benefit society and advance the Smart City development in line with the government's blueprint.
The Lifts and Escalators segment's contracts-in-hand amounted to HK$563 million. During the Year, Anlev Elevator Group ("Anlev"), the Group's global brand of lifts, escalators, and moving walkways, completed the installation of Hong Kong's first commercial puzzle-stacking automated parking system, which advances "Smart Mobility" in Hong Kong, with the form of flexible automated parking system (APS). Designed by Anlev, the APS leverages innovative technology to provide 30 to 100 percent more parking spaces within the same footprint to alleviate the shortage of parking space in Hong Kong, enhance traffic planning and bring greater convenience to motorists. Following the success of the first APS project, Anlev was awarded a further contract to provide an APS for the new government building in the Kai Tak Development Area. For overseas markets, the alliance with TEI, one of the largest independent lift and escalator companies in New York, effectively enhanced the Group's operational and technical capabilities, and widened its service offering to international customers. The Group's new market strategy is also evidenced by the establishment of its first lifts and escalators company in the United Kingdom.
"On the green initiatives front, I am pleased that the Group has become the first E&M engineering group in Hong Kong to obtain a Sustainable Finance Certification from the Construction Industry Council and achieve the Green Loan Pre-Issuance Stage Certificate under the Green and Sustainable Finance Certification Scheme launched by the Hong Kong Quality Assurance Agency, as well as issuing a green financing instrument that will go towards enhancing water and wastewater management. In continuing this green journey, we are actively collaborating with prominent universities to develop more green energy and innovative environmental solutions," added Dr Poon.
In 2022, despite the emergence of the fifth wave of COVID-19 in Hong Kong having hampered the pace of economic recovery, on-going significant investments in infrastructure, the "Smart City" initiatives, the rise of IoT, as well as the rapid development of the Greater Bay Area are expected to present tremendous opportunities to Analogue. The outlook remains positive for the Group, which has been able to focus on its well-established foundation and innovative culture to sustain the operation through the uncertainties.
Dr Poon concluded, "Good opportunities arise even amidst challenging times. With strong business fundamentals and a sound financial position, we are well-positioned to grasp the growth opportunities ahead. Apart from organic growth, we will continue our efforts in exploring M&A opportunities in different parts of the world to support our expansion plans, with priorities placed on companies that have synergistic effects. 2022 marks the 45th anniversary of the Group. Over the past decades, we have dealt with numerous challenges, and have grown stronger from such experiences. With our pioneering spirit, utmost determination, wealth of experience and solid foundation, we are confident in achieving our expansion plans and propelling Analogue to new heights."
About Analogue Holdings Limited Established in 1977, Analogue Holdings Limited is a leading electrical and mechanical engineering service provider headquartered in Hong Kong, with operations in Macau, Mainland China, the United States and the United Kingdom. Serving a wide spectrum of customers from public and private sectors, the Group provides multi-disciplinary and comprehensive E&M engineering and technology services in four major segments, including Building Services, Environmental Engineering, Information, Communications and Building Technologies ("ICBT") and Lifts & Escalators.
The Group also manufactures and sells Anlev lifts and escalators internationally and has entered into an alliance with Transel Elevator & Electric Inc. ("TEI Group"), one of the largest independent lifts and escalators companies in New York, the United States. The Group's associate partner, Nanjing Canatal Data Centre Environmental Tech Company Limited (603912.SS), is specialised in manufacturing of precision air conditioners.
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comAnalogue Holdings Limited ("Analogue" or the "Company", together with its subsidiaries, collectively the "Group") (stock code: 1977), a leading electrical and mechanical ("E&M") engineering service provider in Hong Kong, today announced its annual results for the year ended 31 December 2021 ("the Year" or "FY2021") with revenue and net profit growth, posting a solid performance amid the pandemic and global uncertainty.
By FintechNews staff -We have seen dramatic growth in FinTech during the pandemic. As the banks shut down, people largely relied on virtual financial services. For example, in the United States, 59% of Americans use more fintech apps now than they did prior to the pandemic. With all these changes happening, we highlight 3 […]
Coinweb, a layer-2 blockchain interoperability protocol, announced today the addition of the Ethereum underlying chain to its expandable blockchain infrastructure. This integration lays the groundwork for protocol-level unification of the Bitcoin-derived chains and the Ethereum family of chains. Bitcoin and Ethereum hold the largest portions of capital in the cryptocurrency market. By integrating and unifying […]